Last updated: July 17, 2026

Application No. 18/780,727

METHODS OF TREATING HEART FAILURE WITH HIBERNATING MYOCARDIUM USING MODIFIED FORMS OF TRIMETAZIDINE

Non-Final OA

Filed

Jul 23, 2024

Priority

Dec 10, 2020 — provisional 63/123,721 +1 more

Examiner

TRAN, ERIC

Art Unit

1629

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Imbria Pharmaceuticals Inc.

OA Round

1 (Non-Final)

Interview Optional

— +23.6% interview lift. Examiner has a relatively high allowance rate (70%); +23.6% interview lift. A written response may suffice.

Based on 104 resolved cases, 2023–2026

Examiner Intelligence

TRAN, ERIC View full profile →

Grants 70% — above average

Career Allowance Rate

73 granted / 104 resolved

+10.2% vs TC avg

Strong +24% interview lift

Without

With

+23.6%

Interview Lift

resolved cases with interview

Typical timeline

2y 9m

Avg Prosecution

40 currently pending

Career history

138

Total Applications

across all art units

Statute-Specific Performance

§101

1.8%

-38.2% vs TC avg

§103

44.7%

+4.7% vs TC avg

§102

12.7%

-27.3% vs TC avg

§112

16.0%

-24.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 104 resolved cases

Prosecution Timeline

Jul 23, 2024

Application Filed

Jun 01, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/073,782

Patent 12643881

BICYCLIC AMINE CDK12 INHIBITORS

3y 6m to grant Granted Jun 02, 2026

16/831,399

Patent 12636288

METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION

6y 2m to grant Granted May 26, 2026

17/788,393

Patent 12637440

NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF

3y 11m to grant Granted May 26, 2026

17/279,705

Patent 12622895

ANTI-NEURODEGENERATIVE COMBINATIONS AND USE FOR TREATMENT OF NEURODEGENERATIVE DISEASES

5y 1m to grant Granted May 12, 2026

19/094,187

Patent 12617783

HETEROCYCLIC GLP-1R AGONISTS

1y 1m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

70%

Grant Probability

94%

With Interview (+23.6%)

2y 9m (~9m remaining)

Median Time to Grant

Low

PTA Risk

Based on 104 resolved cases by this examiner. Grant probability derived from career allowance rate.